Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

Trainer, Peter; M Drake, William; Katznelson, Laurence; U. Freda, Pamela; Herman-Bonert, Vivien; van der Lely, A.J.; V. Dimaraki, Eleni; M. Stewart, Paul; Friend, Keith; Lee Vance, Mary; M. Besser, G.; O. Thorner, Michael; Parkinson, Craig; Klibanski, Anne; S. Powell, Jeffrey; L. Barkan, Ariel; C. Sheppard, Michael; Maldonado, Mario; Roderick Rose, D.; R. Clemmons, David; Johannsson, Gudmundur; Bengtsson, Bengt‐Åke; Stavrou, Stavros; L. Kleinberg, David; M. Cook, David; S. Phillips, Lawrence; Bidlingmaier, Martin; J. Strasburger, Christian; Hackett, Suzanne; Zib, Kenneth; F. Bennett, William; J. Davis, Robert; A. Scarlett, John

doi:10.1056/nejm200004203421604

Public

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

Published in New England Journal of Medicine • Apr 20, 2000

Authors:

Peter Trainer

William M Drake

Laurence Katznelson

Abstract

BACKGROUND: Patients with acromegaly are currently treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone-receptor antagonist that blocks the...

Subject

Pegvisomant

Acromegaly

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!